manufacturing, and customer need for amorphous solid dispersion (ASD) by spray drying a critical technology that improves drug solubility, bioavailability, and stability makes this expansion essential in order to meet the need for more innovative therapeutics
* Its scale vs access
Over the past five years, the global weight-loss drug market has evolved from GLP-1 single-target to dual-target therapies, driving peptides from early research into large-scale commercial development
39(4): 51426 Mitchell SC, Zhang AQ, Smith RL
Obesity Three of the GLP-1 RAs are FDA approved for obesity: liraglutide (Victoza, Saxenda), semaglutide (Ozempic, Wegovy), and tirzepatide (Mounjaro, Zepbound) (these have separate brands for diabetes and obesity, and we have listed the diabetes brand first)